Brainshake has raised 3.5 million euros in Series A funding. The investment will be used to advance regulatory approval and internationalization of its blood analysis service.
Brainshake’s blood analysis service provides more than 220 biomarkers from a single blood sample – 50 times more than commonly used laboratory methods. Biomarkers reflect the health state of an individual and can be used to predict disease risk in chronic diseases. Brainshake’s blood analysis, backed up by over 100 scientific publications, is used by leading universities globally.
“Our technology has been proven by peer-reviewed science and the epidemiological studies show the power of our data in risk assessment of chronic diseases. Now we are bringing the technology to routine healthcare with the ultimate target to enable prevention of the world’s number one health problem”, says Teemu Suna, CEO, Brainshake.
The 3.5 million investment is led by Cor Group, a Finnish growth venture, joining Brainshake as a shareholder and long-term strategic partner. Other parties of the financial package include Tekes, Nordea and Finnvera. Brainshake is also a member of one of the world’s biggest health-focused start-up accelerators StartUp Health.
“We have worked in the global health care market for nearly 30 years, and consider Brainshake’s blood analysis highly impressive. We look forward to working together to create a global market leader and to advance the company’s mission to transform preventive medicine in chronic diseases together with our Group. Our goal is to work with Brainshake as a long-term strategic partner, as an active member of the board and co-owner”, says Olli Karhi, board member, Cor Group.
Helsinki-based Brainshake has 15 employees in Finland. In 2015, the company’s turnover was 1,6 million euros of which over 95% came from export.
Our latest health headlines delivered to your inbox.